Valion Bio, Inc. (VBIO): Entry into a Material Definitive Agreement
Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On July 31, 2026, the Company issued an aggregate of 1,287.8685 shares of Series A Preferred Stock (“Milestone Shares”), as consideration for the Milestone Payment (as discussed in more detail in
How this was made
The 30-second read
Why it matters
This 8-K adds a new material definitive agreement disclosure and describes equity consideration (Series A preferred stock milestone shares) tied to milestone payments, including potential future milestone payments payable in cash or company stock at management’s discretion.
Market read
The filing is relevant for traders underwriting dilution and milestone execution risk in a clinical-stage biotech licensing model.
What to watch
Traders should focus on the probability-weighted timing of the listed FDA events (BLA filing and approvals) and whether the company can fund development without additional raises before those milestones.
Background
Valion Bio (formerly Tivic Health Systems) previously licensed Statera’s TLR5 agonist program Entolimod for Acute Radiation Syndrome, with an option for additional indications.
Ticker impact
Valion Bio entered a material definitive agreement and issued Series A preferred stock milestone shares to Statera and Avenue tied to development milestones.
Near-term volatility possible as traders price the likelihood/timing of future milestones and any equity issuance from milestone payments.
The filing is a primary disclosure of a material agreement and equity issuance tied to specific FDA and clinical milestones, but it does not provide the full economic terms beyond the milestone-share issuance and capped payment structure.
Market effects
Adds another example of biotech licensing deals where milestone payments can be satisfied with stock, influencing how investors underwrite small-cap clinical-stage funding risk.
None specific beyond US small-cap biotech sentiment.
Limited, as the disclosure is company-specific and FDA milestone oriented.
Counterpoint
Equity-settled milestone payments may be less dilutive than cash if the company’s stock is strong at milestone dates, and the deal could de-risk the ARS and subsequent indication roadmap.
Key entities
- issuerValion Bio, Inc.
Nasdaq-listed company disclosing entry into a material definitive agreement and related equity issuance.
- counterpartyStatera Biopharma, Inc.
Licensor of the Entolimod TLR5 agonist program under the exclusive license framework.
- counterpartyAvenue Capital (Avenue Venture Opportunities Fund, L.P.)
Receives certain milestone payments directly on behalf of Statera under the amended license agreement structure.
